Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 8/20 | 0.43 |
| ▸ | CA1 | P00915 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172094 | 1.00 | KMT2A (0.47) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5873743 | 0.87 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL5873740 | 0.87 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL7008837 | 0.86 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL7008832 | 0.86 | ALDH1A1 (0.43) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5894173 | 0.84 | KMT2A (0.52) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5894167 | 0.84 | KMT2A (0.52) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5873969 | 0.82 | RAB9A (0.42) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5873968 | 0.82 | RAB9A (0.42) | KMT2AMEN1ALDH1A1CA2CA1 | |
| SCHEMBL5873904 | 0.81 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | claimed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | claimed |
| JP-2003502280-A | — | — | 2003-01-21 | — | — | JP | claimed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | claimed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | claimed |
| US-20070213403-A1 | TAMOXIFEN RESPONSE IN PRE-AND POSTMENOPAUSAL BREAST CANCER PATIENTS | FORSKARPATENT I SYD AB (SE) | 2007-09-13 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | disclosed |
| US-6624171-B1 | Useful as cyclin dependent kinase 11 inhibitors, for preventing/reducing the severity of epithelial cytotoxicity side-effects (e.g., alopecia, plantar- palmar syndrome, mucositis) induced by chemotherapy and/or radiation therapy | SMITHKLINE BEECHAM CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1180105-B1 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-05-14 | — | — | EP | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | KMT2A 2347/4885MEN1 3674/4885ALDH1A1 3290/4885 |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | CCNI, AZI2, CDKN1A | KMT2A 1279/4885MEN1 3806/4885ALDH1A1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.